See more : SoftBank Group Corp. (SFTBY) Income Statement Analysis – Financial Results
Complete financial analysis of Alphamab Oncology (9966.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alphamab Oncology, a leading company in the Biotechnology industry within the Healthcare sector.
- Kempower Oyj (KEMPOWR.HE) Income Statement Analysis – Financial Results
- Séché Environnement SA (0OG6.L) Income Statement Analysis – Financial Results
- GLOBALFOUNDRIES Inc. (GFS) Income Statement Analysis – Financial Results
- Hunan Tianrun Digital Entertainment &Cultural Media Co.,Ltd. (002113.SZ) Income Statement Analysis – Financial Results
- AVG Logistics Limited (AVG.BO) Income Statement Analysis – Financial Results
Alphamab Oncology (9966.HK)
About Alphamab Oncology
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 218.77M | 166.85M | 146.02M | 0.00 | 4.99M | -735.00K | 1.22M |
| Cost of Revenue | 55.24M | 44.21M | 3.03M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 163.54M | 122.64M | 142.99M | 0.00 | 4.99M | -735.00K | 1.22M |
| Gross Profit Ratio | 74.75% | 73.50% | 97.93% | 0.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 407.52M | 468.24M | 481.36M | 331.24M | 166.65M | 65.61M | 53.22M |
| General & Administrative | 79.34M | 86.77M | 77.25M | 78.21M | 154.30M | 13.32M | 6.63M |
| Selling & Marketing | 0.00 | 169.00K | 299.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 79.34M | 86.94M | 77.55M | 78.21M | 154.30M | 13.32M | 6.63M |
| Other Expenses | -323.33M | 473.00K | 5.36M | 0.00 | -4.99M | -27.37M | 40.00K |
| Operating Expenses | 163.54M | 468.02M | 570.04M | 480.60M | 315.96M | 96.02M | 65.06M |
| Cost & Expenses | 542.32M | 512.23M | 573.06M | 480.60M | 315.96M | 96.02M | 65.06M |
| Interest Income | 74.04M | 19.66M | 14.63M | 52.83M | 29.35M | 423.00K | 205.00K |
| Interest Expense | 12.18M | 14.21M | 13.18M | 0.00 | 3.61M | 1.51M | 8.00K |
| Depreciation & Amortization | 69.12M | 55.19M | 41.10M | 18.98M | 1.83M | 266.00K | 101.00K |
| EBITDA | -129.30M | -391.83M | -358.13M | -390.47M | -277.57M | -91.93M | -64.92M |
| EBITDA Ratio | -59.10% | -234.85% | -265.10% | 0.00% | -16,373.42% | 17,026.67% | -5,257.89% |
| Operating Income | -305.55M | -432.37M | -415.62M | -409.45M | -829.13M | -131.71M | -64.82M |
| Operating Income Ratio | -139.66% | -259.15% | -284.63% | 0.00% | -16,609.25% | 17,919.46% | -5,299.92% |
| Total Other Income/Expenses | 94.96M | 82.75M | -10.43M | -18.32M | -553.34M | -110.43M | 197.00K |
| Income Before Tax | -210.59M | -325.72M | -412.42M | -427.77M | -832.74M | -202.63M | -64.83M |
| Income Before Tax Ratio | -96.26% | -195.22% | -282.44% | 0.00% | -16,681.49% | 27,569.12% | -5,300.57% |
| Income Tax Expense | 0.00 | 40.31M | 28.28M | 0.00 | 3.61M | 16.63M | -31.77M |
| Net Income | -210.59M | -325.72M | -412.42M | -427.77M | -836.35M | -149.84M | -33.06M |
| Net Income Ratio | -96.26% | -195.22% | -282.44% | 0.00% | -16,753.73% | 20,386.80% | -2,703.27% |
| EPS | -0.22 | -0.35 | -0.44 | -0.46 | -1.56 | -0.17 | -0.04 |
| EPS Diluted | -0.22 | -0.35 | -0.44 | -0.46 | -1.56 | -0.17 | -0.04 |
| Weighted Avg Shares Out | 959.90M | 930.63M | 935.49M | 929.75M | 536.53M | 897.01M | 897.01M |
| Weighted Avg Shares Out (Dil) | 959.90M | 936.50M | 935.49M | 929.75M | 536.53M | 897.01M | 897.01M |
Late-Breaking Research – Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003
Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023
Source: https://incomestatements.info
Category: Stock Reports